The first of the case-control consortia, called Interlymph, was spearheaded by Trisha Hartge and others at NCI. It currently involves 22 centers and over 18,000 cases of non-Hodgkin lymphoma mainly in the U.S. and Europe, plus Canada, the West Indies, Egypt, and Australia.